Department of Surgery, Faculty of Medicine, Kurume University, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.
Anticancer Res. 2011 Jul;31(7):2547-52.
Leukocytapheresis (LCAP) is a recent modality for treatment of patients with ulcerative colitis (UC). This study aimed to assess whether LCAP changed the development of colorectal cancer (CRC) in patients with UC.
A total of 42 patients with UC underwent surgical treatment from January 2001 until October 2010 at Kurume University Hospital. The patient details, preoperative therapy, operative indication and complications were obtained from our prospective database. Univariate, multivariate analysis and tree model were used for statistical analysis.
In patients who received LCAP before surgery, CRC was significantly less frequent (p=0.0321). CRC incidence following LCAP increased when the disease period from diagnosis of UC exceeded 133 months. Multivariate analysis showed that the odds for undergoing LCAP were significantly higher (p=0.0305) in those cases with a total dose of steroid more than 2.57 g.
LCAP may suppress CRC in UC patients.
白细胞吸附疗法（LCAP）是一种治疗溃疡性结肠炎（UC）患者的新方法。本研究旨在评估 LCAP 是否改变了 UC 患者结直肠癌（CRC）的发展。
2001 年 1 月至 2010 年 10 月，共有 42 例 UC 患者在久留米大学医院接受了手术治疗。我们从前瞻性数据库中获得了患者详细信息、术前治疗、手术指征和并发症。采用单因素、多因素分析和树模型进行统计分析。
在接受手术前接受 LCAP 的患者中，CRC 的发生率明显较低（p=0.0321）。在 UC 诊断后疾病期超过 133 个月时，接受 LCAP 后 CRC 的发生率增加。多因素分析显示，在接受类固醇总剂量超过 2.57 g 的患者中，接受 LCAP 的可能性显著更高（p=0.0305）。
LCAP 可能抑制 UC 患者的 CRC 发生。
